Skip to main content

Contribution of relapses to disability in multiple sclerosis

Journal of Neurology volume 255, pages 280–287 (2008)Cite this article

Abstract

The impact of relapses on long-term disability in multiple sclerosis remains unclear; however some evidence suggests that relapses play an important role in determining subsequent prognosis. We report on outcome, prognostic factors for recovery and the contribution of relapses to the accumulation of fixed disability in a large series of patients with documented relapses. Two hundred and seventynine relapses in 182 patients were assessed before, during and after relapse by expanded disability status scale and data analysed to assess degree of recovery. Factors affecting outcome were considered including sex, age and site of relapse.

Mean EDSS prior to relapse was 3.73, during relapse 5.18 and post relapse 4.23. Mean interval to post relapse assessment was 127 days post relapse. Mean residual change in EDSS score (pre to post relapse) was 0.50 points. Overall 49.4 % of patients had a residual increase in disability post relapse of at least 0.5 EDSS points and 32.7 % had an increase of at least 1 point. No significant difference was observed in mean residual EDSS for sex, site of relapse or age at relapse or in the proportion of patients with a residual increase in disability of ≥ 1 EDSS point post relapse. 14.4 % of patients had no increase in EDSS score during relapse compared to pre relapse.

These results suggest that acute relapses are commonly associated with an objective worsening of disability in the majority of patients with MS and that recovery is incomplete in approximately half and not influenced by gender, age or site of lesion. Therapies which reduce relapse frequency and/or severity might therefore be expected to slow or prevent worsening of disability if initiated prior to the onset of more permanent damage.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L (1988) Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 45:746–748

    PubMed  CAS  Google Scholar 

  2. Bethoux F, Miller DM, Kinkel RP (2001) Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler 7:137–142

    PubMed  CAS  Google Scholar 

  3. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271–278

    PubMed  Article  CAS  Google Scholar 

  4. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, Spada V, Weiss W, Appel S, Rolak L, et al. (1991) A placebo-controlled, double-blind, randomized, two- center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533–539

    PubMed  CAS  Google Scholar 

  5. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231

    PubMed  Article  Google Scholar 

  6. Confavreux C, Vukusic S (2006) Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 108:327–332

    PubMed  Article  Google Scholar 

  7. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782

    PubMed  Article  Google Scholar 

  8. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L (1986) High-dose intravenous methyl prednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36:238–243

    PubMed  CAS  Google Scholar 

  9. Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing- remitting and secondary progressive multiple sclerosis. Mult Scler 9:260–274

    PubMed  Article  Google Scholar 

  10. Fog T, Linnemann F (1970) The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand 47(Suppl):3–175

    CAS  Google Scholar 

  11. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

    Google Scholar 

  12. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904

    PubMed  Article  CAS  Google Scholar 

  13. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765–772

    PubMed  CAS  Google Scholar 

  14. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL (1977) Studies on the natural history of multiple sclerosis – 8. Early prognostic features of the later course of the illness. J Chronic Dis 30:819–830

    PubMed  Article  CAS  Google Scholar 

  15. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528–1532

    PubMed  Google Scholar 

  16. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    PubMed  Article  CAS  Google Scholar 

  17. Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24- month clinical and MRI outcome. J Neurol 244:153–159

    PubMed  Article  CAS  Google Scholar 

  18. Nos C, Sastre-Garriga J, Borras C, Rio J, Tintore M, Montalban X (2004) Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult Scler 10:413–416

    PubMed  Article  CAS  Google Scholar 

  19. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC (1990) Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40:971–975

    PubMed  CAS  Google Scholar 

  20. O'Connor PW, Goodman A, Willmer- Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62:2038–2043

    PubMed  Google Scholar 

  21. Ozakbas S, Cagiran I, Ormeci B, Idiman E (2004) Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 218:3–7

    PubMed  Article  Google Scholar 

  22. Panelius M (1969) Studies on epidemiological, clinical and etiological aspects of multiple sclerosis. Acta Neurol Scand:Suppl 39:31–82

    Google Scholar 

  23. Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E (2002) Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 105:164–168

    PubMed  Article  CAS  Google Scholar 

  24. Patzold U, Pocklington PR (1982) Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 65:248–266

    PubMed  CAS  Article  Google Scholar 

  25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231

    PubMed  Article  CAS  Google Scholar 

  26. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  27. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the Panel On the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 122:552–568

    PubMed  CAS  Article  Google Scholar 

  28. Smith KJ, McDonald WI (1999) The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354:1649–1673

    PubMed  Article  CAS  Google Scholar 

  29. Waxman SG (2006) Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 7:932–941

    PubMed  Article  CAS  Google Scholar 

  30. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(Pt 6):1419–1428

    PubMed  Article  Google Scholar 

  31. West T, Wyatt M, High A, Bostrom A, Waubant E (2006) Are initial demyelinating event recovery and time to second event under differential control? Neurology 67:809–813

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Clinical Research Fellow in Neurology, Helen Durham Neuro-inflammatory Centre, Dept. of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK, CF14 4XN

    C. Hirst MB, Bch, MRCP &  G. Ingram MB, ChB, MRCP

  2. Specialist Registrar, Dept. of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK, CF14 4XN

    O. Pearson MB, ChB, MRCP

  3. Consultant Neurologist, Helen Durham Neuro-inflammatory Centre, Dept. of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK, CF14 4XN

    T. Pickersgill MB, ChB, MRCP

  4. Consultant Neurologist, University of Bristol Institute of Clinical Neurosciences, Dept. of Neurology, Frenchay Hospital, Bristol, UK, BS16 1LE

    N. Scolding FRCP, PhD

  5. Senior Lecturer and Consultant Neurologist, Helen Durham Neuro-inflammatory Centre, Dept. of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK, CF14 4XN

    N. Robertson MB, BS, MD, FRCP

Authors
  1. C. Hirst MB, Bch, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Ingram MB, ChB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Pearson MB, ChB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Pickersgill MB, ChB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Scolding FRCP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Robertson MB, BS, MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Robertson MB, BS, MD, FRCP.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hirst, C., Ingram, G., Pearson, O. et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 255, 280–287 (2008). https://doi.org/10.1007/s00415-008-0743-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0743-8

Key words

  • multiple sclerosis
  • relapse
  • disability
  • prognosis